SOPHiA GENETICS Announces Closing of $234 Million Initial Public Offering and $20 Million Private Placement
July 27 2021 - 4:05PM
SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data
pooling and knowledge sharing platform that advances data-driven
medicine, announced today the closing of its initial public
offering of 13,000,000 ordinary shares at a price of $18 per share.
The gross proceeds from the offering, before deducting underwriting
discounts and commissions and estimated fees and offering expenses
payable by SOPHiA GENETICS SA, are $234 million. In addition,
SOPHiA GENETICS SA has granted the underwriters an option to
purchase up to 1,950,000 additional ordinary shares at the initial
public offering price, less underwriting discounts and commissions.
The ordinary shares began trading on the Nasdaq Global Select
Market on July 23, 2021 under the symbol “SOPH.”
In addition, SOPHiA GENETICS SA announced today the
closing of a private placement, in which it issued and sold
1,111,111 ordinary shares to an affiliate of GE Healthcare. The
gross proceeds from the private placement, before deducting
estimated expenses payable by SOPHiA GENETICS SA, are $20 million.
The sale of ordinary shares in the private placement was made
pursuant to an exemption from the registration requirements of the
U.S. Securities Act of 1933, as amended.
J.P. Morgan, Morgan Stanley, Cowen and Credit
Suisse acted as joint book-running managers for the initial public
offering.
A registration statement relating to the securities
sold in the initial public offering has been filed with, and
declared effective by, the U.S. Securities and Exchange Commission.
The initial public offering was made only by means of a prospectus.
Copies of the prospectus relating to the offering may be obtained
from J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by
telephone at (212) 834-4533 or by email at
prospectus-eq_fi@jpmchase.com; Morgan Stanley & Co. LLC, Attn:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY
10014, by telephone at (866) 718-1649 or by email at
prospectus@morganstanley.com; Cowen and Company, LLC, c/o
Broadridge Financial Solutions, Attn: Prospectus Department, 1155
Long Island Avenue, Edgewood, NY 11717, by telephone at (833)
297-2926 or by email at PostSaleManualRequests@broadridge.com; and
Credit Suisse Securities (USA) LLC, Attn: Prospectus Department,
6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at
(800) 221-1037 or by email at usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer to
sell or the solicitation of an offer to buy any securities, nor
shall there be any sale of any securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
There is no intention to publicly offer, solicit,
sell or advertise, directly or indirectly, any securities, or
invest in securities of SOPHiA GENETICS SA, such as the ordinary
shares, in, into or from Switzerland and the securities will not be
listed on the SIX Swiss Exchange or on any other exchange or
regulated trading venue in Switzerland. The ordinary shares may not
be publicly offered, directly or indirectly, in Switzerland within
the meaning of the Swiss Financial Services Act ("FinSA"), except
under an exemption from the prospectus requirements under the
FinSA. No application has or will be made to admit the ordinary
shares to trading on any trading venue (exchange or multilateral
trading facility) in Switzerland. Neither this document nor any
other offering or marketing material relating to any securities,
such as the ordinary shares, constitutes or will constitute a
prospectus pursuant to the FinSA, and neither this document nor any
other offering or marketing material relating to the ordinary
shares constitutes a prospectus pursuant to the FinSA, and neither
this document nor any other offering or marketing material relating
to the ordinary shares may be publicly distributed or otherwise
made publicly available in Switzerland in a manner which would
require the publication of a prospectus pursuant to the FinSA.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare
technology company dedicated to establishing the practice of
data-driven medicine as the standard of care and for life sciences
research. It is the creator of the SOPHiA DDM™ Platform, a
cloud-based SaaS platform capable of analyzing data and generating
insights from complex multimodal data sets and different diagnostic
modalities. The SOPHiA DDM™ Platform and related solutions,
products and services are currently used by more than 780 hospital,
laboratory and biopharma institutions globally.
Media
Contact:sophiagenetics@consortpartners.com
Investor Contact:Carrie
Mendivilcarrie@gilmartinir.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024